Contineum Therapeutics Income Statement (2023-2026) | CTNM

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter) 50.00M
Operating items
Research & Development (Quarter) 3.63M9.46M6.50M8.01M7.78M7.90M9.73M13.02M13.71M14.06M10.99M12.76M11.65M
Selling, General & Administrative (Quarter) 1.48M1.60M1.57M1.66M2.15M3.04M3.25M4.03M4.40M3.84M3.94M4.36M5.26M
Operating Expenses (Quarter) 5.12M11.06M8.07M9.68M9.93M10.94M12.97M17.05M18.11M17.90M14.93M17.11M16.90M
Operating Income (Quarter) -5.12M38.94M-8.07M-20.87M-9.93M-10.94M-12.97M-17.05M-18.11M-17.90M-14.93M-17.11M-16.90M
EBIT (Quarter) -5.12M38.94M-8.07M-20.87M-9.93M-10.94M-12.97M-17.05M-18.11M-17.90M-14.93M-17.11M-16.90M
Non-operating items
Interest & Investment Income (Quarter) 0.40M0.68M1.74M1.79M1.64M2.00M2.74M2.53M2.25M2.03M1.96M2.01M2.50M
Other Non Operating Income (Quarter) -0.02M-0.08M-0.04M0.26M-0.01M-0.08M-0.03M-0.05M-0.13M-0.17M0.18M-0.05M-0.06M
Non Operating Income (Quarter) 0.29M3.36M1.70M-0.05M-0.01M1.94M2.71M-0.05M-0.13M-0.17M2.41M8.20M-0.06M
Net income details
EBT (Quarter) -4.82M42.30M-6.37M-7.93M-8.42M-9.01M-10.27M-14.56M-15.86M-15.87M-12.97M-15.11M-14.40M
Tax Provisions (Quarter) 0.70M-0.10M-0.16M
Profit After Tax (Quarter) -4.82M41.56M-6.25M-7.77M-8.42M-9.01M-10.27M-14.56M-16.00M-16.04M-12.80M-15.18M-14.50M
Income from Continuing Operations (Quarter) -4.82M41.60M-6.27M-7.77M-8.42M-9.01M-10.27M-14.56M-15.86M-15.87M-12.97M-15.11M-14.40M
Consolidated Net Income (Quarter) -4.82M41.60M-6.27M-7.77M-8.42M-9.01M-10.27M-14.56M-15.86M-15.87M-12.97M-15.11M-14.40M
Income towards Parent Company (Quarter) -4.82M41.60M-6.27M-7.77M-8.42M-9.01M-10.27M-14.56M-15.86M-15.87M-12.97M-15.11M-14.40M
Net Income towards Common Stockholders (Quarter) -4.82M41.60M-6.27M-7.77M-8.42M-9.01M-10.27M-14.56M-15.99M-16.04M-12.79M-15.11M-14.40M
Additional items
EPS (Basic) (Quarter) -2.122.56-2.69-0.53-3.55-0.39-0.40-0.57-0.62-0.62-0.45-0.49-0.39
EPS (Weighted Average and Diluted) (Quarter) 0.84-2.69-0.35-0.39-0.40-0.57-0.62-0.55-0.39
Shares Outstanding (Weighted Average) (Quarter) 2.29M2.29M2.33M2.31M2.37M12.86M25.73M19.35M25.87M25.90M28.12M27.70M37.34M
Shares Outstanding (Diluted Average) (Quarter) 19.35M25.87M27.70M37.34M
EBITDA (Quarter) -4.76M41.51M-6.28M-7.57M-8.58M-9.08M-9.58M-15.05M-15.89M-16.06M-12.67M-15.16M-14.97M
Interest Expenses (Quarter) 0.09M0.12M
Shares Outstanding (Quarter) 2.27M2.32M2.33M2.35M15.91M6.73M19.01M6.73M19.14M19.19M22.77M31.24M32.72M
Tax Rate (Quarter) 1.651.572.03